Amgen Statement on Complete Response Letter from the U.S. FDA for ABP 980, a Biosimilar Candidate to Herceptin (Trastuzumab)

Amgen received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) in response to the Biologics License Application (BLA) for ABP 980, a biosimilar candidate to Herceptin® (trastuzumab).

We will work closely with the FDA to bring this important medicine to patients in the U.S. We do not expect this to impact our U.S launch plan.

To read more Press Release articles, click here.